Concert Pharmaceuticals Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 81

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 15

Concert Pharmaceuticals General Information

Description

Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Former Stock Listing
CNCE
Corporate Office
  • 65 Hayden Avenue
  • Suite 3000N
  • Lexington, MA 02421
  • United States
+1 (781) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Concert Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Concert Pharmaceuticals‘s full profile, request access.

Request a free trial

Concert Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop smal
Biotechnology
Lexington, MA
81 As of 2023
00000
00000 0000-00-00
000000&0 00000

000000

lor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut l
0000000000000
Zug, Switzerland
000 As of 0000
00000
000000000 00000

000000

uip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
0000 000000000
Boston, MA
0000 As of 0000
00.000
0000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Concert Pharmaceuticals Competitors (47)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
Vertex Pharmaceuticals Formerly VC-backed Boston, MA 0000 00.000 000000&0
Quince Therapeutics Formerly VC-backed South San Francisco, CA 00 00000 000000&0
Alzheon Venture Capital-Backed Framingham, MA 00 00000 00000000000 00000
Aileron Therapeutics Formerly VC-backed Watertown, MA 0 00000 000000000 00000
You’re viewing 5 of 47 competitors. Get the full list »

Concert Pharmaceuticals Patents

Concert Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2018188474-A Deuterated cftr potentiator Active 13-Aug-2018 0
JP-2018172421-A Deuteration derivatives of ruxolitinib Active 05-Jul-2018 0
AU-2019239096-A1 Deuterated analogs of d-beta-hydroxybutyric acid and uses thereof Inactive 23-Mar-2018 000000000
US-20210008018-A1 Deuterated analogs of d-beta-hydroxybutyric acid and uses thereof Inactive 23-Mar-2018 000000000
CA-3093430-A1 Deuterated analogs of d-.beta.-hydroxybutyric acid and uses thereof Inactive 23-Mar-2018 A61K31/19
To view Concert Pharmaceuticals’s complete patent history, request access »

Concert Pharmaceuticals Executive Team (8)

Name Title Board Seat Contact Info
Ian Silverman Ph.D Senior Vice President & General Counsel
Justine Koenigsberg Senior Vice President, Corporate Communications and Investor Relations
You’re viewing 2 of 8 executive team members. Get the full list »

Concert Pharmaceuticals Board Members (13)

Name Representing Role Since
000000 0000000 Self Board Member 000 0000
0000000 000000 00 Three Arch Partners Board Member 000 0000
You’re viewing 2 of 13 board members. Get the full list »

Concert Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Concert Pharmaceuticals Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Concert Pharmaceuticals‘s full profile, request access.

Request a free trial

Concert Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated July, 04, 2021

30.21 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,042

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 947

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 427

Rank

00.00

Percentile

To view Concert Pharmaceuticals’s complete esg history, request access »

Concert Pharmaceuticals FAQs

  • When was Concert Pharmaceuticals founded?

    Concert Pharmaceuticals was founded in 2006.

  • Who is the founder of Concert Pharmaceuticals?

    Roger Tung Ph.D is the founder of Concert Pharmaceuticals.

  • Where is Concert Pharmaceuticals headquartered?

    Concert Pharmaceuticals is headquartered in Lexington, MA.

  • What is the size of Concert Pharmaceuticals?

    Concert Pharmaceuticals has 81 total employees.

  • What industry is Concert Pharmaceuticals in?

    Concert Pharmaceuticals’s primary industry is Biotechnology.

  • Is Concert Pharmaceuticals a private or public company?

    Concert Pharmaceuticals is a Private company.

  • What is the current valuation of Concert Pharmaceuticals?

    The current valuation of Concert Pharmaceuticals is 00000.

  • What is Concert Pharmaceuticals’s current revenue?

    The current revenue for Concert Pharmaceuticals is 000000.

  • How much funding has Concert Pharmaceuticals raised over time?

    Concert Pharmaceuticals has raised $333M.

  • Who are Concert Pharmaceuticals’s investors?

    Adage Capital Management, Brookside Capital, Fidelity Investments, Flagship Pioneering, and Foresite Capital are 5 of 15 investors who have invested in Concert Pharmaceuticals.

  • Who are Concert Pharmaceuticals’s competitors?

    CRISPR Therapeutics, Vertex Pharmaceuticals, Quince Therapeutics, Alzheon, and Aileron Therapeutics are some of the 47 competitors of Concert Pharmaceuticals.

  • When was Concert Pharmaceuticals acquired?

    Concert Pharmaceuticals was acquired on 06-Mar-2023.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »